Mummery CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al. Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. Nat Med 2023 Apr 24. doi: 10.1038/s41591-023-02326.
PMID: 37095250